Pharmaceutical Advisory — Market Access · Regulatory · Communications
We turn evidence into strategic advantage.
For over two decades, the world's leading pharmaceutical companies have trusted Meta-Works to build the evidence cases that win market access, defend submissions, and withstand the toughest regulatory scrutiny.
The Mandate
In a top-down drug budget, the difference between access and rejection is measured in tens of millions of dollars — and years of delay. We exist to close that gap.
Meta-Works is a specialist pharma advisory firm building evidence-case marketing and economic resources for complex, data-dependent portfolio decisions.
We mine new insight from integrated bodies of evidence using rigorous statistical and epidemiological methodology — evidence built to survive scrutiny, reused with confidence across regulatory and commercial contexts.
A near-perfect strike rate on projects that progress from our initial feasibility study — from two-person scopes to multidisciplinary teams of ten or more experts.
Areas of Practice
By objective · By role
Regulatory Fluency
Fluent in the language of the world's toughest agencies.
We prepare and defend evidence before the bodies that decide whether a medicine reaches patients — in Australia and across every major market. When the scrutiny is highest, our work holds.
By the Numbers
Two decades, measured
Since 1999 · Clinical, economic and societal impact: incalculable · Track record: unparalleled
Notable Projects
A selection
Listing of biologics onto Essential Medicines Lists and public-sector formularies across LMICs.
IPO evidence production and value presentation for public-market scrutiny.
Salvaging submissions — reworking regulatory and pricing cases under pressure.
Regional socio-economic footprint studies for industry and government audiences.
Troubleshooting evidentiary risk from government initiatives and new market entrants.
HTA policy advisory to trade bodies and associations, globally.
Step your knowledge up. Free, forever.
Join more than 300,000 listeners getting sharper on evidence, access and the business of medicine.